The licensing deal highlights the active role of DelSiTech Ltd in formulation development space of controlled release veterinary drugs.
Finnish drug delivery and development Company DelSiTech Ltd announced today that it has signed a technology licensing agreement with Solani Therapeutics Ltd. Solani Therapeutics is a Finnish drug development company specialized in novel veterinary therapeutics for pets. Under the terms of the agreement, Solani Therapeutics obtains worldwide exclusive rights to develop and commercialize a certain product for treatment of a chronic disease in companion animals, based on DelSiTech’s drug delivery technology platform. DelSiTech is entitled to receive undisclosed license and milestone fees as well as royalties on product sales.
Solani Therapeutics’ CEO Mrs. Elina Niskanen said “Solani has been searching for the right technology for controlled release of veterinary drugs for a while, and we found DelSiTech’s biodegradable silica based technology best for our purposes”
DelSiTech’s CEO Dr. Lasse Leino said ”We are naturally very pleased about the collaboration with Solani Therapeutics. Animal Health is one of our focus areas as our technology is well suited for administration of parenteral therapeutics in companion animals and lifestock”